Pharmaceutical

ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despite CB

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

May 20, 2025 - 06:00
ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despite CB
Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.
Read the original article

Tags:

Previous Article

Pfizer signs global licensing deal with 3SBio for bispecific antibody

Next Article

ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Jabil acquires CDMO Pii to support drug development customers

Jabil acquires CDMO Pii to support drug development cus...

Feb 5, 2025

STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs

STAT+: Medicare may plan to negotiate drug prices, but ...

Oct 12, 2023

STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves

STAT+: At JPM, Bristol’s new CEO appeals to history to ...

Jan 8, 2024